Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Blood (2022) 139 (9): 1340–1358.

https://doi.org/10.1182/blood.2020010344

Published: 2022

Includes: Supplemental data

Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Blood (2021) 137 (25): 3473–3483.

https://doi.org/10.1182/blood.2020009688

Published: 2021

Includes: Supplemental data

Journal Articles

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

William Blum, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Sebastian Schwind, MD, Yao Jiang, Jiang Wang, Mitch Phelps, PhD, Susan Geyer, PhD, Steven M. Devine, MD, Kathy Walsh, MD, Sumithira Vasu, MBBS, John P. Curfman, Larry Schaaf, PhD, Celia Garr, RN, Cheryl Kefauver, RN, John C. Byrd, MD, Michael R. Grever, MD, Ramiro Garzon, MD, Guido Marcucci, MD

Blood (2012) 120 (21): 2619.

https://doi.org/10.1182/blood.V120.21.2619.2619

Published: 2012

Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3104.

https://doi.org/10.1182/blood.V110.11.3104.3104

Published: 2007

Journal Articles

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

William Blum, MD, Rebecca B. Klisovic, MD, Amy Johnson, PhD, Cheryl Kefauver, RN, Mitch Phelps, PhD, David Lucas, PhD, Lenguyen Huynh, Shujun Liu, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Guido Marcucci, MD, John C. Byrd, MD

Blood (2007) 110 (11): 890.

https://doi.org/10.1182/blood.V110.11.890.890

Published: 2007

Journal Articles

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Thomas S. Lin, MD, PhD, Mitch Phelps, PhD, James T. Dalton, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Dimitrios Colevas, MD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2006) 108 (11): 2845.

https://doi.org/10.1182/blood.V108.11.2845.2845

Published: 2006

Journal Articles

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

William Blum, MD, Rebecca B. Klisovic, MD, Cheryl Kefauver, RN, Amy Johnson, PHD, Mitch Phelps, James T. Dalton, David Lucas, PHD, LeNguyen Huynh, Shujun Liu, Michael R. Grever, MD, A.D. Colevas, Guido Marcucci, MD, John C. Byrd, MD

Blood (2006) 108 (11): 4578.

https://doi.org/10.1182/blood.V108.11.4578.4578

Published: 2006

NARROW

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

Email alerts

ASH Publications

American Society of Hematology

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only